Case File
efta-efta01136565DOJ Data Set 9OtherFrom: Eileen Alexanderson
Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta01136565
Pages
2
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From: Eileen Alexanderson
To: "Jeffrey Epstein ([email protected])" <[email protected]>
Subject: Phaidon
Date: Fri, 12 Apr 2013 22:06:43 +0000
Attachments: img-412173234-0001.pdf
Jeffrey, See Phaidon org structure attached.
Mechanics of the purchase were as follows:
PLB LLC was funded with $54mi1 from the Black Family 1997 Trust, $3mi1 from the Black Family 1997 GST
Exempt Trust, and $l0mil from the LDB 2011 LLC. JMWT LLC was funded with $67,000 from Leon. These
provided funding for the JMWT Acquisition LLP. Bidco (JMWT Ltd) purchased the shares of Phaidon Press Ltd.
The acquisition purchase price paid from JMWT Ltd (through client account at Macfarlanes) was £41,000,000 +
.005 stamp tax ($67mi1).
In between, 2/3 of the funds were booked into the Topco as equity and 1/3 into the Midco as debt. From a US
perspective the funds into JMWT Ltd were treated as an equity contribution. This debt is just between the topco
and the midco and was established for UK interest deductibility purposes and be converted to equity if we
choose. Great care was taken to avoid creating phantom income.
Profit or loss at Phaidon Press level has no impact for us until we choose to issue a dividend. The one issue I
believe you will need to consider if Phaidon was to purchase are relates to the US tax aspects of subpart F
income and whether Phaidon owning art (or eventually selling it at a gain) would create that type of income. I
believe it might.
As I mentioned this morn, I have a call on Monday morning set with the tax guy at PWC-you are welcome to
join-he is flexible re what time.
Best, E.
Original Message
From: NY_730_11_XRX_COPYROOM [mailto:[email protected]]
Sent: Friday, April 12, 2013 5:33 PM
To: Eileen Alexanderson
Subject: Scan from a Xerox Color
Please open the attached document. It was scanned and sent to you using a Xerox Color.
Number of Images: 1
Attachment File Type: PDF
Device Name: NY 730 11 XRX COPYROOM
_
_ _
_
Device Location:
For more information on Xerox products and solutions, please visit http://www.xerox.com/
This email and any files transmitted with it are confidential
and intended solely for the person or entity to whom they are
EFTA01136565
addressed and may contain confidential and/or privileged
material. Any review, retransmission, dissemination or
other use of, or taking of any action in reliance upon this
information by persons or entities other than the intended
recipient is prohibited. If you have received this email in
error please contact the sender and delete the material from
any computer.
Apollo Global Management, LLC
EFTA01136566
Technical Artifacts (4)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Related Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.